Three additional Lauriad-based products could begin clinical studies this year.

BioAlliance Pharma reported positive preliminary results from a Phase III trial evaluating acyclovir Lauriad®, its mucooadhesive buccal tablet for the treatment of orofacial herpes. Compared with placebo, acyclovir Lauriad shortened the time from first prodromal symptoms to healing and reduced healing time for patients presenting with primary vesicular lesions.

A higher percentage of patients in the acyclovir Lauriad group also demonstrated abortive lesions (i.e., without vesicular lesion). The single-dose, placebo-controlled trial included 722 patients with recurrent orofacial herpes.

BioAlliance’s acyclovir Lauriad product is based on the same, patented mucoadhesive buccal tablet technology as Loramyc®, the company’s product for treating oropharyngeal candidiasis in immunocompromised patients. Loramyc has been approved in a number of European countries and just yesterday was sanctioned by the Swiss regulatory authorities. An FDA submission for Loramyc was also recently accepted.

Bioalliance is developing three additional products using the Lauriad® technology. These include fentanyl Lauriad, clonidine Lauriad, and corticosteroid Lauriad. In its annual report for 2008 the company said clinical trials with the three products could start during 2009.

Previous articleWhen Is Revenue Not Revenue for Biotech Firms?
Next articleEuropean Commission Clears Wyeth Drug for Relapsed and Refractory Mantle Cell Lymphoma